We guide early- and mid-stage device programs from concept to clinic — integrating translational feasibility analysis, regulatory pathway definition, and quantitative modeling to align design, cost, and risk.

Hands-on experience building and scaling science-driven ventures. We help founders translate research into investable business models through structured diligence, non-dilutive funding strategy, and investor readiness.

Expertise in SBIR/STTR, DoD OTA & FAR, and BARDA programs. We develop compliant technical narratives and budget models, quantifying program milestones to maximize scoring potential and reduce execution risk.

From concept initiation to regulatory submission, we bring structured, quantitative program governance — integrating risk matrices, scenario modeling, and decision dashboards to keep science and capital aligned.

Strategic support across the development continuum, from preclinical validation through lifecycle management. We model probability-of-success and milestone value to inform capital allocation and partnering strategy.

Frameworks for assessing, prioritizing, and advancing novel technologies. We combine qualitative insight with quantitative forecasting to identify which innovations are both technically and commercially defensible.

We help investors and operators quantify the relationship between technical progress and valuation. Services include milestone-based modeling, burn-rate forecasting, and R&D portfolio optimization.

Advisory on practical integration of AI and data automation within R&D and operational pipelines. We design workflows that use machine learning to improve prediction, resource allocation, and decision quality.